TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01434225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
Study: NCT01252966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control training
Description: The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
Study: NCT01733706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No nicotine electronic cigarette
Description: The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: standard counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: standard counseling
Study: NCT00337532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
Study: NCT02655861

Intervention type: OTHER
Intervention: Observation
Study: NCT02189382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxalate

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Study: NCT00725738

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: 1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes.
Study: NCT02720068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion
Study: NCT03924297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chilipad
Description: Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
Study: NCT03545841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT
Description: Participants completed 6 weeks of HIT
Study: NCT02720068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT03545841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT
Description: Participants completed 6 weeks of MICT
Study: NCT02720068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT00560599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mupirocin and chlorhexidine
Description: Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: household cleaning and disinfection
Description: Environmental cleaning with topical ethanol and laundering of clothes and linen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mupirocin, chlorhexidine, & household cleaning/disinfection
Description: Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen.
Study: NCT03478878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A Palmitate
Description: Provide vitamin A to participants with pre/post assessments of vision.
Study: NCT02720068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV infusion
Study: NCT00586547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion Dose Level -1
Description: (1 x 10\^3 T cells/Kg)
Study: NCT02720068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (Calcium Folinate)
Description: IV infusion
Study: NCT05334095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perclose ProGlide
Description: After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angio-seal VIP
Description: After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP
Study: NCT04438564

Intervention type: OTHER
Group type: OTHER
Intervention: Cases for patients diagnosed with breast cancer, colonrectal cancer, ovarian cancer and endometrial cancer
Description: Diagnosis and acceptance of breast cancer, colon rectal cancer, ovarian cancer, and endometrial cancer by the clinical Western medicine team.
Study: NCT00103727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talnetant
Description: talnetant
Study: NCT02720068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (Calcium Folinate)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil [5-FU]
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil [5-FU]
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral
Study: NCT03905772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary exercise
Description: The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
Study: NCT00586547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion Dose Level 1
Description: (1 x 10\^4 T cells/Kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion Dose Level 2
Description: (1 x 10\^5 T cells/Kg)
Study: NCT03905772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wide pulse responder group
Description: The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wide pulse non responder group
Description: The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed current group
Description: The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
Study: NCT01623466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: transdermal contraceptive delivery system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: transdermal contraceptive delivery system
Study: NCT00949338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre-procedural preparation
Description: Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-procedural preparation
Description: Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
Study: NCT00332657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: One 0.5 mL injection into the PJD at 6-month intervals for 42 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/mL
Description: One 0.5 mL injection into the PJD at 6-month intervals for 42 months

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
Study: NCT01186653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide / formoterol
Description: budesonide / formoterol, 400 micrograms/9 micrograms one IH bd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
Study: NCT03251690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine/Rilpivirine
Description: Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine/Efavirenz
Description: as a active comparator
Study: NCT01713348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Navigator
Description: Masked CGM day 1 to 15, unmasked CGM days 15 to 100

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard SMBG
Description: Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
Study: NCT00652821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol/ APAP
Description: Tablets 37.5mg /325mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet
Description: Tablets, 37.5mg/325mg
Study: NCT02985801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo Oral Capsule
Study: NCT03551886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Emotion App
Description: The app is designed to help TAY better recognize their emotions using enhanced features

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Emotion App
Description: The app is designed to help TAY better recognize their emotions using basic features
Study: NCT02928419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag/Revolade
Description: From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
Study: NCT02755636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCPHC
Description: Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Primary care as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Primary care as usual
Study: NCT03864354

Intervention type: PROCEDURE
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
Study: NCT02952742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black Cohosh
Description: Vital Nutrients Black Cohosh Extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
Study: NCT02525172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immune globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT02976831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0284
Description: Oral solution, concentration: 2 mg/mL and 15 mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching AZD0284 in the form of an oral solution with water.
Study: NCT03202121

Intervention type: OTHER
Intervention: insomnia group
Description: After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
Study: NCT00586547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion Dose Level 3
Description: (1 x 10\^6 T cells/Kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Cell Infusion- Dose Level 4
Description: (5 x 10\^6 T cells/Kg)
Study: NCT03202121

Intervention type: OTHER
Intervention: non-insomnia group
Description: After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.

Intervention type: OTHER
Intervention: normal control
Description: Persons without stroke or insomnia served as normal controls that contained 25 cases.
Study: NCT02750566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
Study: NCT01712360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT500 (pediatric)
Description: Applied to both feet and groin area
Study: NCT02042001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate switch to TDF/FTC/RPV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switch to TDF/FTC/RPV after 24 weeks
Description: Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
Study: NCT01712360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT600 (pediatric)
Description: Applied to both feet only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT500 (adult)
Description: Applied to both feet and groin area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAFT600 (adult)
Description: Applied to both feet
Study: NCT01887444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17938 probiotic
Description: Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
Study: NCT00147771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.